Changjian Shao

Changjian Shao

Auto-generated profile, based on publicly available information

Changjian Shao

Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi’an, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2022 in Journal of Pineal Research
Verified
Journal Article
Closed access
YWYuan yong Wang
Yuan yong Wang
ZWZhaoyang Wang
Zhaoyang Wang
CSChangjian Shao
Changjian Shao
GLGuofang Lu
Guofang Lu
MXMei Xie
Mei Xie
XYXiaolong Yan
Xiaolong Yan

28 October 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
HDHongtao Duan
Hongtao Duan
CSChangjian Shao
Changjian Shao
ZLZhilin Luo
Zhilin Luo
TWTianhu Wang
Tianhu Wang
LTLiping Tong
Liping Tong
XYXiaolong Yan
Xiaolong Yan
This open-label, single-arm, phase 2 trial evaluated the efficacy and safety of neoadjuvant sintilimab combined with anlotinib and chemotherapy, followed by adjuvant sintilimab, for resectable NSCLC. Forty-five patients received anlotinib (10 mg, QD, PO, days 1–14), sintilimab (200 mg, day 1), and platinum-based chemotherapy of each three-week cycle for 3 cycles, followed by surgery within 4–6 weeks. Adjuvant sintilimab (200 mg) was administered every 3 weeks. The primary endpoint was achieving a pathological complete response (pCR). From June 10, 2021 through October 10, 2023, 45 patients were enrolled and composed the intention-to-treat population. Twenty-six patients (57.8%) achieved pCR, and 30 (66.7%) achieved major pathological response (MPR). Forty-one patients underwent surgery. In the per-protocol set (PP set), 63.4% (26/41) achieved pCR, and 73.2% achieved MPR. The median event-free survival was not attained (95% CI, 25.1-NE). During the neoadjuvant treatment phase, grade 3 or 4 treatment-related adverse events were observed in 25 patients (55.6%), while immune-related adverse events were reported in 7 patients (15.6%). We assessed vascular normalization and infiltration of immune-related cells by detecting the expression of relevant cell markers in NSCLC tissues with mIHC. Significant tumor microenvironment changes were observed in pCR patients, including reduced VEGF+ cells and CD4+Foxp3+ Treg cells, and increased perivascular CD4+ T cells, CD39+CD8+ T cells, and M1 macrophages. In conclusion, perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy achieved pCR in a notable proportion of patients with resectable NSCLC and were associated with profound changes in the tumour microenvironment (ClinicalTrials.gov NCT05400070).